# OnCo record gc012f (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/gc012f/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "gc012f" ;
  schema:name "GC012F"@en ;
  schema:description "GC012F is an experimental CAR-T cell therapy from Gracell Biotechnologies (Shanghai) in phase 2 trials for multiple myeloma, aimed at CD19 and BCMA."@en ;
  schema:url <https://onco.cc/drugs/gc012f/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=GC012F> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "CAR-T cell therapy" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/bcma/> ;
  onco:companies <https://onco.cc/companies/gracell-biotechnologies/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/nct06235229/> .